- Home
- CELU vs DTIL Comparison
CELU vs DTIL Comparison
Compare CELU & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELU | DTIL |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 123.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CELU | DTIL |
|---|---|---|
| Price | $1.81 | $4.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $47.00 |
| AVG Volume (30 Days) | 62.1K | ★ 227.5K |
| Earning Date | 11-14-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,578,000.00 | $698,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $76.00 | $34.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $3.61 |
| 52 Week High | $4.35 | $8.82 |
Technical Indicators
Market Signals| Indicator | CELU | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 39.42 |
| Support Level | $1.62 | $4.70 |
| Resistance Level | $2.01 | $5.20 |
| Average True Range (ATR) | 0.12 | 0.38 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 23.81 | 27.03 |
Price Performance
Historical ComparisonAbout CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.